相关临床试验
283
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1988
进行中（未招募）
9
3.2%
已完成
206
72.8%
尚未招募
5
1.8%
招募中
31
10.9%
暂停
1
0.3%
终止
17
6.0%
撤回
14
5.0%
暂无批准数据
- The 2025-2030 Dietary Guidelines for Americans now recommend 1.2–1.6 g/kg/day of protein, up from the long-standing 0.8 g/kg/day, particularly for weight management in overweight and obesity. - A new Perspective in The Journal of Nutrition acknowledges the guideline's strengths but argues evidence is insufficient to justify a universal higher-protein recommendation for all Americans across the lifespan. - Experts note that protein needs vary by age, activity level, health status, and goals, with groups such as those over 40, on GLP-1 medications, or with cardiometabolic diseases potentially benefiting most. - Authors call for additional research to understand protein needs across diverse populations and life stages to strengthen future dietary guidance.
- Pennington Biomedical Research Center is recruiting participants for a clinical trial testing CagriSema, a novel weight loss drug combining GLP-1 and amylin peptides. - The study aims to determine whether the amylin component helps preserve muscle mass and mitigates the drop in resting metabolic rate during weight loss. - Participants are randomized to drug or placebo, both targeting 10% weight loss through a reduced-calorie diet and increased physical activity. - Dr. Eric Ravussin notes modern weight loss drugs can achieve 25-30% weight loss, calling the current era "spectacular" for obesity research.
- Researchers at LSU's Pennington Biomedical Research Center identified a previously underappreciated role for peroxisomes in protecting insulin and maintaining beta cell health and maturity. - Disrupting peroxisomes in animal models promoted oxidative stress, altered insulin's chemical structure, and reduced markers of mature beta cell identity. - Despite increased insulin secretion, animals with impaired peroxisomal function developed glucose intolerance, indicating that more insulin does not guarantee better blood sugar control. - The findings, published in JCI Insight, point to new questions about whether peroxisomal pathways could be relevant to metabolic disease in humans.
- A triple-blind clinical trial involving 24 obese adults demonstrated that Pep19, a synthetic peptide, achieved a 17% reduction in visceral fat over 60 days without affecting lean body mass. - The study showed that both 2mg and 5mg doses of Pep19 improved sleep quality in all participants, with the peptide administered orally once daily before bedtime. - Researchers found that Pep19 works through the endocannabinoid system to regulate metabolism and can transform white fat into metabolically active brown fat. - The collaborative research between Pennington Biomedical, Proteimax Biotechnology, and ICB-USP revealed no side effects, supporting the peptide's potential as a safe therapeutic option for metabolic health.
- Answer ALS has launched LADDIA, a groundbreaking AI-powered drug discovery collaboration with GATC Health, Pennington Biomedical Research Center, and Tulane University to accelerate ALS treatment development. - The initiative leverages the world's largest open-access ALS dataset through the Neuromine Data Portal and GATC Health's proprietary AI platform to identify druggable therapeutic targets. - Currently, there are no known viable treatments for ALS, making this AI-driven approach critical for identifying new therapeutic pathways for the neurodegenerative disease. - The collaboration will roll out in two phases, focusing first on building infrastructure and then activating collaborative projects to generate high-impact scientific outputs.
- New research reveals that stage III colon cancer patients who engage in high levels of physical activity (≥18.0 MET-hours/week) show survival rates comparable to the general population. - Analysis of two major NCI-sponsored trials demonstrates that patients with low physical activity (<3.0 MET-hours/week) experienced 17.1% lower survival rates compared to matched general population. - The survival benefit of physical activity was most pronounced in patients who remained tumor recurrence-free for three years, highlighting the importance of both cancer control and lifestyle factors.
